TAKTakedaFinished
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
ALK+ Advanced NSCLC
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 248 (final count)
- Started
- Apr 19, 2019
- Main results expected
- Feb 27, 2024
- Fully finished
- Sep 18, 2024
- Results posted
- Feb 19, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1
Measured over: Up to 33.8 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03596866 · record last updated 2025-09-12 · checked 2026-11-09 15:47 UTC